Buyback of Class B shares in Essity during week 3, 2026

Essity repurchased 66,186 Class B shares between January 12–16, 2026 under its SEK 3bn buyback program, paying a weekly weighted average price of SEK 267.3059 for a total of SEK 17,691,908. The program, announced April 23, 2025, has accumulated 9,361,016 repurchased shares valued at SEK 2,420,216,478; following the latest trades Essity holds 10,143,516 Class B treasury shares out of 693,054,489 total shares outstanding. Purchases were executed on Nasdaq Stockholm by BofA Securities Europe and financed from operating cash flow after the ordinary dividend, with management signalling buybacks will remain a recurring element of capital allocation.

Analysis

Market structure: The buyback materially supported near-term supply/demand by removing ~9.36m shares from the market (≈1.35% of 693.05m outstanding) and leaving Essity with 10.14m treasury B-shares (~1.46% of shares) — a meaningful float reduction for a large-cap Nordic name. Direct winners are existing ESSITY.ST holders (EPS accretion, price support) and short-sellers (short squeeze risk); marginal losers are liquidity providers and option sellers facing compressed IV. Cross-asset effects are small but discernible: modest corporate credit signaling (cash-outflow SEK ~2.42bn spent vs SEK3bn program leaving ~SEK580m capacity) and slightly firmer SEK versus Scandinavian peers if buybacks persist.

Risk assessment: Tail risks include a sudden halt to buybacks (program near exhaustion with ~SEK580m remaining), a dividend funding squeeze if cash flow weakens, or regulatory/insider scrutiny over treasury share use; operational risks (pricing, raw material inflation, FX) could reverse gains. Immediate impact (days–weeks) is price support and lower realized volatility; short-term (1–3 months) depends on AGM decisions and Q1 sales; longer-term (quarters) fundamentals (market share, margin trends) dominate. Hidden dependency: buybacks financed after the ordinary dividend implies capital allocation trade-offs (M&A vs returns) that could shift if management pivots.

Trade implications: With program nearly exhausted, price support may fade after the AGM — create short-duration tactical positions to harvest buyback premium and medium-term fundamental longs for core exposure. Options strategies (sell covered calls or cash-secured puts) monetize near-term support while limiting downside; pair trades long ESSITY.ST vs consumer staples peers exploit buyback-driven outperformance. Key catalysts: AGM (before 2026 Annual General Meeting), Q1 reporting, and any announced extension of buyback policy.

Contrarian angles: Consensus may overstate persistent buyback support — only ~SEK580m capacity remains, so the market may be underpricing potential normalization of float and volatility post-program. Historical parallels: buyback-fueled pops in European staples often retrace 30–70% of the initial move within 3–6 months absent fundamental improvement. Unintended consequences: treasury shares could be deployed for M&A or employee schemes, diluting future returns or changing governance dynamics.

Key Decisions for Investors

• Establish a 2% portfolio long position in ESSITY.ST at market, add up to 1% more if price < SEK 250; target exit 295–310 SEK within 6–12 months, set hard stop-loss at 10% below entry (≈244 SEK if entry ~271 SEK) to limit downside if buyback support evaporates.
• Implement an income overlay: sell 3-month cash-secured puts on ESSITY.ST at SEK 250 only if premium ≥ SEK 7.5 (≥3% payoff); alternatively sell 3-month covered calls at SEK 290 for premiums ≥2% to monetize near-term buyback support while capping upside.
• Run a relative-value pair: long ESSITY.ST (2%) vs short KMB (Kimberly‑Clark, 1% notional) for 6–12 months to capture expected buyback-driven outperformance; trim if spread narrows <200bp of total return or if KMB announces defensive buybacks.
• Reassess positions within 60 days around the 2026 AGM and Q1 results: if management announces new buyback >SEK 0.5bn or raises capital allocation guidance, increase long to 3–4%; if net debt/EBITDA rises >0.5x from last reported, reduce exposure by 50%.